Protein,Protein_definition,Disease_category,Disease,Method,Nb_SNP,OR[95%CI],P_value
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter I Certain infectious and parasitic diseases,Other bacterial agents as the cause of diseases classified to other chapters,Inverse variance weighted,55,1.07 [0.88-1.30],0.479400741419382
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter X Diseases of the respiratory system,Later onset COPD,Inverse variance weighted,55,0.99 [0.96-1.03],0.566899822487461
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism,Other and unspecified anaemias,Inverse variance weighted,55,1.02 [0.99-1.04],0.221365336945114
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Acidosis,Inverse variance weighted,55,1.00 [0.87-1.13],0.94283525192282
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases","Other disorders of fluid, electrolyte and acid-base balance",Inverse variance weighted,55,1.01 [0.98-1.04],0.489064883504763
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Hyperkalaemia,Inverse variance weighted,55,0.98 [0.89-1.07],0.631867198851853
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases","Hyperlipidaemia, other/unspecified",Inverse variance weighted,55,1.01 [0.98-1.05],0.471004319153317
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Hypokalaemia,Inverse variance weighted,55,1.04 [0.99-1.10],0.107531404255103
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Hypo-osmolality and hyponatraemia,Inverse variance weighted,55,0.99 [0.95-1.03],0.642831171041426
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Disorders of lipoprotein metabolism and other lipidaemias,Inverse variance weighted,55,1.00 [0.99-1.02],0.688993141888045
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Metabolic disorders,Inverse variance weighted,55,1.01 [0.99-1.02],0.33885394253033
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Disorders of magnesium metabolism,Inverse variance weighted,55,1.00 [0.79-1.26],0.996216207794961
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Disorders of mineral metabolism,Inverse variance weighted,55,1.04 [0.98-1.11],0.226692686203664
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases",Obesity,Inverse variance weighted,55,1.00 [0.98-1.02],0.817437892449311
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,"Chapter IV Endocrine, nutritional and metabolic diseases","Obesity, other/unspecified",Inverse variance weighted,55,1.01 [0.98-1.04],0.418763311012008
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter VI Diseases of the nervous system,Falls/tendency to fall,Inverse variance weighted,55,1.00 [0.99-1.01],0.660985389508224
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Atrial fibrillation and flutter,Inverse variance weighted,55,0.99 [0.97-1.01],0.286308564223966
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Conduction disorders,Inverse variance weighted,55,0.97 [0.94-1.00],0.051791531235097
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Coronary atherosclerosis,Inverse variance weighted,55,0.98 [0.96-1.00],0.023012308550295
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,"Heart failure, strict",Inverse variance weighted,55,0.99 [0.97-1.01],0.259916231212726
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Hypotension,Inverse variance weighted,55,1.04 [0.99-1.09],0.0900863054537832
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,"Hypertension, essential",Inverse variance weighted,55,1.00 [0.98-1.02],0.914515256892725
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Hypertension,Inverse variance weighted,55,1.00 [0.99-1.02],0.565388780341167
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,"Hypertension, Pulmonary Arterial",Inverse variance weighted,55,0.94 [0.78-1.13],0.526485563738302
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,"Ischaemic heart disease, wide definition",Inverse variance weighted,55,0.99 [0.97-1.00],0.096008373105793
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Death due to cardiac causes,Inverse variance weighted,55,0.99 [0.97-1.01],0.316327812332358
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Other or ill-defined heart diseases,Inverse variance weighted,55,0.97 [0.90-1.05],0.43646804357767
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Other peripheral vascular diseases,Inverse variance weighted,55,0.99 [0.93-1.06],0.797678927531603
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Paroxysmal tachycardia,Inverse variance weighted,55,0.98 [0.95-1.01],0.122780406108983
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter IX Diseases of the circulatory system,Secondary right heart disease,Inverse variance weighted,55,1.01 [0.93-1.11],0.74606371204799
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter X Diseases of the respiratory system,Influenza and pneumonia,Inverse variance weighted,55,1.00 [0.98-1.01],0.585051345374178
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter X Diseases of the respiratory system,Chronic lower respiratory diseases,Inverse variance weighted,55,1.00 [0.99-1.02],0.60455042799251
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter X Diseases of the respiratory system,Other diseases of pleura,Inverse variance weighted,55,0.97 [0.94-1.00],0.0280152810292366
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter X Diseases of the respiratory system,Pleural effusion,Inverse variance weighted,55,0.97 [0.93-1.01],0.169859633223921
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter V Mental and behavioural disorders,Any mental disorder,Inverse variance weighted,55,0.99 [0.98-1.01],0.318700036319768
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter V Mental and behavioural disorders,"Substance abuse, excluding more controls",Inverse variance weighted,55,0.97 [0.95-0.99],0.0022496529711124
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIII Diseases of the musculoskeletal system and connective tissue,Other arthrosis,Inverse variance weighted,55,1.01 [0.99-1.04],0.356715219072386
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIII Diseases of the musculoskeletal system and connective tissue,Osteopathies and chondropathies,Inverse variance weighted,55,0.99 [0.96-1.01],0.183687255580757
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIII Diseases of the musculoskeletal system and connective tissue,Osteoporosis,Inverse variance weighted,55,0.97 [0.93-1.01],0.0921616205739658
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIII Diseases of the musculoskeletal system and connective tissue,Polyarthropathies,Inverse variance weighted,55,1.01 [1.00-1.03],0.153792843222082
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIV Diseases of the genitourinary system,Acute renal failure,Inverse variance weighted,55,0.99 [0.95-1.04],0.815454646603037
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIV Diseases of the genitourinary system,Renal tubulo-interstitial diseases,Inverse variance weighted,55,0.99 [0.97-1.01],0.410854522773554
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter XIV Diseases of the genitourinary system,Other disorders of urethra and urinary system,Inverse variance weighted,55,0.98 [0.96-1.00],0.0432564088690341
ENPP5,Ectonucleotide pyrophosphatase/phosphodiesterase family member 5,Chapter V Mental and behavioural disorders,Smoking dependency,Inverse variance weighted,55,1.00 [0.94-1.06],0.978409079051282
